Covaxin third phase clinical trials results out, 77.8 per cent effective against Covid-19
Covaxin has also been found to be 65.2 percent effective against the dreaded Delta variant of Coronavirus, which is becoming the dominant strain of the virus across the world.
Share Via Email
| A+A A- By Express News Service
HYDERABAD: Covaxin, the Covid-19 vaccine developed by Hyderabad-based vaccine maker Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been found to be 77.8 percent effective in the Phase-III clinical trials.
Also, Covaxin has been found to be 93.4% effective against severe symptomatic form of Covid-19 and 63.6 percent effective against asymptomatic Covid-19.
Covaxin 77 8% effective against Covid-19: Bharat Bio - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Bharat Biotech says that the final efficacy analysis of Covaxin shows it to be 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission. This paves the way for Covaxin to get World Health Organisation s approval for its inclusion in the Emergency Use List of Covid-19 vaccines. The company added that the analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19. The safety analysis demonstrates that adverse events reported were similar to placebo, with 12 per cent of the subjects experiencing commonly known side effects and less than 0.5 per cent of them feeling serious adverse effects. The efficacy data further demonstrates 63.6 per cent protection against asympt
Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid
By IANS |
93 Views
Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid. Image Source: IANS News
New Delhi, July 3 : Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
Bharat Biotech has concluded final analysis for Covaxin efficacy from Phase 3 clinical trials.
Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19. Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects feeling serious adverse events.
URL copied Image Source : PTI
Covaxin gives 77.8 per cent efficacy against COVID 19, and 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant
Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19. It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant. Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19, the company said.
vimarsana © 2020. All Rights Reserved.